Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
CASE REPORT
Catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus
Online publication date: 2013-03-05
Reumatologia 2013;51(1):73-76
KEYWORDS
ABSTRACT
The aim of the study was to describe two case reports of probable catastrophic antiphospholipid syndrome (CAPS) in systemic lupus erythematosus (SLE) patients, following gastrointestinal infections.
Case 1: a 53-year-old man was diagnosed with probable CAPS based on multiorgan thrombosis (pulmonary emboli, myocardial infarction, acute renal failure) and high levels of antiphospholipid antibody markers. Moreover, the patient fulfilled the SLE criteria. The symptoms developed after gastrointestinal infection. Case 2: a 48-year-old woman with long-term history of SLE and antiphospholipid syndrome, whose conditions worsened after gastrointestinal infection, was diagnosed with CAPS based on pulmonary microemboli, thrombosis of the portal vein, lower limb thrombophlebitis, and acute renal failure. Both the cases were treated with heparin, steroids in pulses, cyclophosphamide, and intravenous immunoglobulins, which resulted in subsidence of symptoms.
Case 1: a 53-year-old man was diagnosed with probable CAPS based on multiorgan thrombosis (pulmonary emboli, myocardial infarction, acute renal failure) and high levels of antiphospholipid antibody markers. Moreover, the patient fulfilled the SLE criteria. The symptoms developed after gastrointestinal infection. Case 2: a 48-year-old woman with long-term history of SLE and antiphospholipid syndrome, whose conditions worsened after gastrointestinal infection, was diagnosed with CAPS based on pulmonary microemboli, thrombosis of the portal vein, lower limb thrombophlebitis, and acute renal failure. Both the cases were treated with heparin, steroids in pulses, cyclophosphamide, and intravenous immunoglobulins, which resulted in subsidence of symptoms.
REFERENCES (20)
1.
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2.
Hughes GR. Hughes syndrome (the antiphospholipid syndrome): a disease of our time. Inflammopharmacology 2011; 19: 69-73.
3.
Zimmermann-Górska I. Kryteria klasyfikacyjne dla zespołu antyfosfolipidowego – kolejna modyfikacja. Pol Arch Med Wewn 2006; 65: 396-400.
4.
Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with SLE. J Rheumatol 2002; 29: 2531-2536.
5.
Choojitarom K, Verasertniyom O, Totemchokchyakarn K, et al. Lupus nephritis and Raynaud’s phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol 2008; 27: 345-351. .
6.
Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54: 2568-2576.
7.
Majdan M, Siwiec A, Majdan A. Zespół antyfosfolipidowy – wybrane problemy poruszane w piśmiennictwie w 2011 roku. W: Reumatologia 2011/2012 nowe trendy. Wiland P (red.). Termedia, Poznań 2012; 153-175.
8.
Cervera R, Tektonidou MG, Espinosa G, et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus 2011; 20: 165-173.
9.
Cervera R, Tektonidou MG, Espinosa G, et al. Task Force on Catastrophic Antiphospholipd Syndrome (APS) and non-criteria ma-nifestations (II): thrombocytopenia and skin manifestations. Lupus 2011; 20: 174-181.
10.
Baker WF, Bick RL. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am 2008; 22: 33-52. .
11.
Bucciarelli S, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: treatment, prognosis, and risk of relapse. Clin Rev Allergy Immunol 2009; 36: 80-84.
12.
Cervera R; CAPS Registry Project Group. Catastrophic antiphospholipid syndrome (CAPS): update from the 'CAPS Registry'. Lupus 2010; 19: 412-418. .
13.
Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010; 10: 74-79.
14.
Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62: 388-393.
15.
Ząbek J. Zakażenia a zespół antyfosfolipidowy. Pol Arch Med Wewn 2007; 117: 61-64.
16.
Stojanovich L. The catastrophic antiphospholipid syndrome in Serbia: diagnostic and management problems. Clinic Rev Allerg Immunol 2009; 36: 98-103. .
17.
García-Carrasco M, Galarza-Maldonado C, Mendoza-Pinto C, et al. Infections and antiphospholipid syndrome. Clinic Rev Allerg Immunol 2009; 36: 104-108.
18.
Wielosz E, Dryglewska M, Majdan M. Antiphospholipid antibodies and kidney involvement in patients with systemic sclerosis. Clin Rheumatol 2009; 28: 955-959. .
19.
Cervera R. Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 2010; 12: 70-76.
20.
Majdan M. Zespół antyfosfolipidowy a choroby nerek. Pol Merk Lek 2010; 28: 341-344.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
